Triacetin- and tributyrin-based formulations dose-dependently promoted butyrate production and enriched IBS-depleted microbial taxa while inducing limited gas formation, suggesting a favorable fermentation profile that may help mitigate IBS symptom severity.
Triacetin dose-dependently increased total short-chain fatty acid levels starting from 100 mg/day.
Active Biome™ and Bio Complete 3™ formulations promoted acetate, butyrate, and propionate production, with BC3 inducing a particularly pronounced butyrate increase.
Triacetin, Active Biome™, and Bio Complete 3™ enriched IBS-depleted, butyrate-associated OTUs related to Faecalibacterium and Anaerobutyricum species.
Active Biome™ and Bio Complete 3™ increased microbial diversity as measured by the community modulation score (CMS) by promoting Bifidobacteriaceae, Lachnospiraceae, and Bacteroidaceae.
All triacetin and triacetin/tributyrin-containing formulations produced stronger SCFA increases with milder gas formation compared to the benchmark prebiotic inulin.
The study applied the validated ex vivo SIFR® technology pipeline using fecal microbiota from eight adults with IBS as its experimental model.
This research suggests that triacetin (TA) and tributyrin (TB)-based dietary formulations can beneficially alter the gut bacterial communities of people with irritable bowel syndrome (IBS). Using a laboratory model that ferments fecal samples from IBS patients outside the body, researchers found that triacetin alone increased levels of beneficial short-chain fatty acids (SCFAs)—particularly acetate and butyrate—in a dose-dependent manner, meaning higher doses produced more of these beneficial compounds. Two finished supplement formulations (Active Biome™ and Bio Complete 3™) that contain triacetin and/or tributyrin went further, also boosting propionate, with Bio Complete 3™ showing an especially strong butyrate effect. Importantly, all of the tested formulations produced these beneficial SCFA increases with less gas formation than inulin, a commonly used prebiotic fiber. This is potentially significant for IBS patients, who often experience painful bloating and gas as symptoms. The formulations also selectively enriched specific bacterial species—including Faecalibacterium and Anaerobutyricum—that are known to produce butyrate and are typically depleted in the guts of IBS patients. The two finished formulations additionally increased overall microbial diversity by promoting beneficial bacterial families including Bifidobacteriaceae, Lachnospiraceae, and Bacteroidaceae. This research suggests that triacetin- and tributyrin-based supplements may help restore a healthier gut microbial balance in IBS by boosting butyrate-producing bacteria and SCFA levels while avoiding excessive gas production. However, because this was a preclinical ex vivo study—meaning it was conducted in a laboratory setting using donated stool samples rather than in living humans—these findings would need to be confirmed in clinical trials before conclusions can be drawn about their effectiveness in IBS patients.
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Upload Your LabsJenkins Sánchez L, Poppe J, Baudot A, Vu L, Villella W, Van den Abbeele P. (2026). Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study.. International journal of molecular sciences. https://doi.org/10.3390/ijms27198910